U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C8H18NO2
Molecular Weight 160.234
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of METHACHOLINE

SMILES

CC(C[N+](C)(C)C)OC(C)=O

InChI

InChIKey=NZWOPGCLSHLLPA-UHFFFAOYSA-N
InChI=1S/C8H18NO2/c1-7(11-8(2)10)6-9(3,4)5/h7H,6H2,1-5H3/q+1

HIDE SMILES / InChI

Molecular Formula C8H18NO2
Molecular Weight 160.234
Charge 1
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019193s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/9622546

Methacholine (trade name Provocholine) is a synthetic choline ester that acts as a muscarinic receptor agonist. Methacholine is primarily used to diagnose bronchial hyperreactivity, which is the hallmark of asthma and also occurs in chronic obstructive pulmonary disease. This is accomplished through the bronchial challenge test, or methacholine challenge, in which a subject inhales aerosolized methacholine, leading to bronchoconstriction.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
PROVOCHOLINE

Approved Use

Provocholine® (methacholine chloride powder for inhalation) is indicated for the diagnosis of bronchial airway hyperreactivity in subjects who do not have clinically apparent asthma.

Launch Date

5.31100795E11
Doses

Doses

DosePopulationAdverse events​
16 mg/mL 5 times / day multiple, respiratory (max)
Recommended
Dose: 16 mg/mL, 5 times / day
Route: respiratory
Route: multiple
Dose: 16 mg/mL, 5 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bronchial airway hyperreactivity
Sources: Page: p.1
Disc. AE: Bronchoconstriction...
AEs leading to
discontinuation/dose reduction:
Bronchoconstriction (severe)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Bronchoconstriction severe
Disc. AE
16 mg/mL 5 times / day multiple, respiratory (max)
Recommended
Dose: 16 mg/mL, 5 times / day
Route: respiratory
Route: multiple
Dose: 16 mg/mL, 5 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bronchial airway hyperreactivity
Sources: Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The effect of acute alteration in oxygen tension on the bronchodilator response to salbutamol in vitro and in vivo in man.
2001
Airway foreign body with clinical features mimicking bronchial asthma.
2001
Bronchial hyperresponsiveness and exhaled nitric oxide in patients with cardiac disease.
2001
Clinical and immunologic changes after allergen immunotherapy with Hop Japanese pollen.
2001 Apr
Glucocorticoid treatment increases inhibitory m(2) muscarinic receptor expression and function in the airways.
2001 Apr
Gibbs sampling-based segregation analysis of asthma-associated quantitative traits in a population-based sample of nuclear families.
2001 Apr
Effects of smooth muscle activation on axial mechanical properties of excised canine bronchi.
2001 Apr
G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype.
2001 Feb
The lack of the bronchoprotective and not the bronchodilatory ability of deep inspiration is associated with airway hyperresponsiveness.
2001 Feb
Oilseed rape flour: another allergen causing occupational asthma among farmers.
2001 Feb
Chronic tobacco smoke exposure increases airway sensitivity to capsaicin in awake guinea pigs.
2001 Feb
Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma.
2001 Jan
Effect of cetirizine on bronchial hyperresponsiveness in patients with seasonal allergic rhinitis and asthma.
2001 Jan
Pulmonary function response to EDTA, an additive in nebulized bronchodilators.
2001 Jan
Relaxant effect of Pimpinella anisum on isolated guinea pig tracheal chains and its possible mechanism(s).
2001 Jan
Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma.
2001 Jan
Hydrocortisone abolishes the angiotensin II-mediated potentiation of endothelin-1 in bovine bronchi.
2001 Jan
[Asthma related to inhalation of Plantago ovata].
2001 Jan 13
Developmental expression of neurokinin A and functional neurokinin-2 receptors in lung.
2001 Jun
SCF-induced airway hyperreactivity is dependent on leukotriene production.
2001 Jun
Possible involvement of Rho kinase in Ca2+ sensitization and mobilization by MCh in tracheal smooth muscle.
2001 Jun
Regulation of secretion from mucous and serous cells in the excised ferret trachea.
2001 Jun
Chronic tobacco smoke exposure increases cough to capsaicin in awake guinea pigs.
2001 Jun
Airway responses to a diluent used in the methacholine challenge test.
2001 Mar
The transcription factor early growth-response factor 1 modulates tumor necrosis factor-alpha, immunoglobulin E, and airway responsiveness in mice.
2001 Mar
Temporal association between airway hyperresponsiveness and airway eosinophilia in ovalbumin-sensitized mice.
2001 Mar
Drug treatment of airway inflammation in asthma.
2001 Mar
Methacholine challenge testing in Reserve Officer Training Corps cadets.
2001 Mar
Tidal midexpiratory flow as a measure of airway hyperresponsiveness in allergic mice.
2001 Mar
Polycystic ovary syndrome is associated with endothelial dysfunction.
2001 Mar 13
Role of K+ channels in N-acetylprocainamide-induced relaxation of bovine tracheal smooth muscle.
2001 Mar 9
Muscarinic depression of synaptic transmission in the epileptogenic GABA withdrawal syndrome focus.
2001 May
Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model.
2001 May
Occupational asthma caused by exposure to cyanoacrylate.
2001 May
Validation of a new questionnaire on asthma, allergic rhinitis, and conjunctivitis in young adults.
2001 May
Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients.
2001 May
Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: impact of budesonide treatment and withdrawal.
2001 May
Patents

Sample Use Guides

Provocholine is inhaled using a standardized procedure. The challenge is performed by giving a subject ascending serial concentrations of Provocholine. At each concentration, five breaths are administered by a nebulizer that permits intermittent delivery time of 0.6 seconds by a breath-actuated timing device (dosimeter). At each of five inhalations of a serial concentration, the subject begins at functional residual capacity (FRC) and slowly and completely inhales the dose delivered. Within 5 minutes, FEV1 values are determined. The procedure ends either when there is a 20% or greater reduction in the FEV1 compared with the baseline sodium chloride solution value (i.e., a positive response) or if 188.88 total cumulative units have been administered and the FEV1 has been reduced by 14 % or less (i.e., a negative response). If there is a reduction of 15% to 19% in the FEV, compared with baseline, either the challenge may be repeated at that concentration or a higher concentration may be given as long as the dosage administered does not result in total cumulative units exceeding 188.88.
Route of Administration: Respiratory
In Vitro Use Guide
Agonist activity of methacholine was determined using assay of accumulation of [3H]inositol monophosphate. The CHO cells were labeled in 12-well plates with 1 uCi/mL myo-[3H]inositol for 24 h. Wells contained ca. 3* 10^5 cells in a volume of 1 mL. Cells were then washed once with Hank’s balanced salt media containing 20 mM HEPES buffer (pH 7.4) and were then incubated in the buffered Hank’s media containing 10 mM LiCl at room temperature for 15 min. Muscarinic agents were then added to each well. After incubation for 1 h at 37 °C, the medium was aspirated and replaced with 750 uL of cold 20 mM aqueous formic acid. After 35 min at 4 °C, the formic acid was removed and replaced with 250 uL of 60 mM NH4OH. The inositol monophosphate in the NH4OH solution was isolated by anionexchange chromatography19 and counted for tritium in Hydrofluor scintillation fluid. Cells were treated with 0.001 - 10 uM of methacholine, EC50 was determined to be 120 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 16 18:35:24 UTC 2022
Edited
by admin
on Fri Dec 16 18:35:24 UTC 2022
Record UNII
03V657ZD3V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHACHOLINE
VANDF   WHO-DD  
Common Name English
1-PROPANAMINIUM, 2-(ACETYLOXY)-N,N,N-TRIMETHYL-, (±)-
Systematic Name English
METHACHOLINE ION
Common Name English
Methacholine [WHO-DD]
Common Name English
METHACHOLINE CATION
Common Name English
METHACHOLINE [VANDF]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175369
Created by admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
NCI_THESAURUS C1937
Created by admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
NDF-RT N0000175884
Created by admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
Code System Code Type Description
IUPHAR
7438
Created by admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
PRIMARY
DAILYMED
03V657ZD3V
Created by admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
PRIMARY
WIKIPEDIA
METHACHOLINE
Created by admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
PRIMARY
RXCUI
155080
Created by admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
PRIMARY RxNorm
EPA CompTox
DTXSID2046967
Created by admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
PRIMARY
CAS
55-92-5
Created by admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
PRIMARY
DRUG BANK
DB06709
Created by admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
PRIMARY
NCI_THESAURUS
C61837
Created by admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
PRIMARY
FDA UNII
03V657ZD3V
Created by admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
PRIMARY
CHEBI
6804
Created by admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
PRIMARY
EVMPD
SUB03201MIG
Created by admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
PRIMARY
DRUG CENTRAL
1726
Created by admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
PRIMARY
PUBCHEM
1993
Created by admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY